Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients | Andersen et al. Journal of Ovarian Research 2010 3 21 http content 3 1 21 RESEARCH JOURNAL OF OVARIAN RESEARCH Open Access Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients John D Andersen1 Kristin LM Boylan1 Ronald Jemmerson2 Melissa A Geller3 Benjamin Misemer1 1 2 v 4 3 5 Katherine M Harrington Starchild Weivoda Bruce A Witthuhn Peter Argenta Rachel Isaksson Vogel Amy PN Skubitz1 Abstract Background New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen CA125 are needed for detection of ovarian cancer in the presurgical setting as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 LRG1 in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease. The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray reverse-transcriptase polymerase chain reaction RT-PCR Western blot immunocytochemistry and mass spectrometry. Results Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women vs. ug ml p and was highest among stage III IV patients. In a separate set of 193 pre-surgical samples LRG1 was higher in patients with serous or clear cell ovarian cancer ug ml compared to patients with benign gynecological diseases ug ml p . CA125 and LRG1 levels were moderately correlated r p . LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR. LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting. Multiple iosforms
